Outlook Therapeutics Inc (OTLK): Next-Year EPS Estimate 53.10%
As of 2026-11-06, Outlook Therapeutics Inc (OTLK) has a next-year EPS growth estimate of 53.10%. Featured in 4 EPS revision reports, most recently on 2026-06-22.
On 2026-11-02, analyst consensus for OTLK's next-year EPS growth shifted from 63.02% to 53.10% — a negative change of 9.92 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at 73.00%.
What's Driving This
OTLK’s rise is primarily tied to a structural EPS estimate upgrade: on 2026-08-19 analysts raised next-year EPS growth from 54.49% to 61.11%, and the current estimate of 63.02% indicates continued upward momentum beyond that initial revision. The plausible catalyst is the FDA approval of LYTENAVA for wet AMD and related Q3 FY2026 business-update and
Generated 2026-10-23 from news as of 2026-10-23
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 53.10%
- EPS growth this year
- 73.00%
- EPS next quarter (est)
- -$0.08
- Last price
- $0.44
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 53.10% | 73.00% | -$0.08 | $0.44 |
| 2026-11-05 | 53.10% | 73.00% | -$0.08 | $0.44 |
| 2026-11-04 | 53.10% | 73.00% | -$0.08 | $0.46 |
| 2026-11-03 | 53.10% | 73.00% | -$0.08 | $0.46 |
| 2026-11-02 | 53.10% | 73.00% | -$0.08 | $0.47 |
| 2026-10-31 | 63.02% | 73.18% | -$0.07 | $0.47 |
| 2026-10-30 | 63.02% | 73.18% | -$0.07 | $0.47 |
| 2026-10-29 | 63.02% | 73.18% | -$0.07 | $0.49 |
| 2026-10-28 | 63.02% | 73.18% | -$0.07 | $0.54 |
| 2026-10-27 | 63.02% | 73.18% | -$0.07 | $0.53 |
| 2026-10-26 | 63.02% | 73.18% | -$0.07 | $0.51 |
| 2026-10-23 | 63.02% | 73.18% | -$0.07 | $0.52 |
| 2026-10-22 | 63.02% | 73.18% | -$0.07 | $0.56 |
| 2026-10-21 | 63.02% | 73.18% | -$0.07 | $0.56 |
| 2026-10-20 | 63.02% | 73.18% | -$0.07 | $0.52 |
| 2026-10-19 | 63.02% | 73.18% | -$0.07 | $0.49 |
| 2026-10-16 | 63.02% | 73.18% | -$0.07 | $0.49 |
| 2026-10-15 | 63.02% | 73.18% | -$0.07 | $0.50 |
| 2026-10-14 | 63.02% | 73.18% | -$0.07 | $0.47 |
| 2026-10-13 | 63.02% | 73.18% | -$0.07 | $0.56 |
| 2026-10-12 | 63.02% | 73.18% | -$0.07 | $0.59 |
| 2026-10-11 | 63.02% | 73.18% | -$0.07 | $0.60 |
| 2026-10-10 | 63.02% | 73.18% | -$0.07 | $0.60 |
| 2026-10-09 | 63.02% | 73.18% | -$0.07 | $0.60 |
| 2026-10-08 | 63.02% | 73.18% | -$0.07 | $0.56 |
| 2026-10-07 | 63.02% | 73.18% | -$0.07 | $0.59 |
| 2026-10-06 | 63.02% | 73.18% | -$0.07 | $0.57 |
| 2026-10-05 | 63.02% | 73.18% | -$0.07 | $0.60 |
| 2026-10-04 | 63.02% | 73.18% | -$0.07 | $0.59 |
| 2026-10-03 | 63.02% | 73.18% | -$0.07 | $0.59 |
Reports Featuring OTLK
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
- 2026-06-18
OTLK Surges 43.6% on FDA News; WDC +41%, FCEL +37.5% Lead EPS Revision Movers
- 2026-06-17
Outlook Therapeutics Soars 50% as EPS Revision and FDA Acceptance Fuel Rally
- 2026-06-16
OTLK, WDC Lead EPS Revision Winners: +42.7% and +33.1% Gains
Recent News
- Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-DemandGlobeNewswire
- Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA in Virtual Investor CEO Connect SegmentGlobeNewswire
- Outlook Therapeutics, Inc. Q3 2026 Earnings Call SummaryMoby
- Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVAGlobeNewswire
- Outlook Therapeutics Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIGStocktwits
- Outlook Therapeutics wins FDA approval for Lytenava in wet AMDPharmaceutical Technology
- Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMDInvestorsHub
- FDA scientists question Capricor data; Legend CEO steps downBioPharma Dive
- OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug Analysts See Nearly 300% UpsideStocktwits
- FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory DecisionsStocktwits
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Outlook Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-06, Outlook Therapeutics Inc (OTLK) has a next-year EPS growth estimate of 53.10%, based on analyst consensus.
When was the latest EPS estimate revision for OTLK?▾
The most recent revision occurred on 2026-11-02, when analysts adjusted the next-year EPS growth estimate from 63.02% to 53.10%.
What sector and industry does Outlook Therapeutics Inc belong to?▾
Outlook Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. OTLK appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Outlook Therapeutics Inc (OTLK) appears here because it was detected by our daily top-EPS-revision-performer screen.